Bosutinib
Treatment for Chronic Myeloid Leukemia
Typical Dosage: 400 mg daily with food
Effectiveness
88%
Safety Score
60%
Clinical Trials
43
Participants
8K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
400 mg daily with food
Time to Effect
3-6 months for major response
Treatment Duration
Lifetime
Evidence Quality
HIGHConfidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$125,000
Monitoring:$2,500
Side Effect Mgmt:$1,000
Total Annual:$128,500
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEQALYs Gained
10
Outcome-Based Costs
Cost per Responder
$197,692
Cost per Remission
$321,250
Comparison vs Imatinib (generic)
Cost Difference
+$117,750/year
More expensive
QALY Difference
+0.10 QALYs
Better outcomes
Dominance
No dominance
Bosutinib Outcomes
for Chronic Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+65%
Remission Rate
+40%
Common Side Effects
Diarrhea
+75%
Nausea
+45%
Vomiting
+35%
Increased transaminases (liver enzymes)
+35%
Myelosuppression
+25%
Sources:
Active Clinical Trials
3 active trials recruiting for Bosutinib in Chronic Myeloid Leukemia
A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
NCT06297161ACTIVE NOT RECRUITING
600 participants
OBSERVATIONAL
New York, United States
Started: Jan 20, 2025
Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia
NCT04258943ACTIVE NOT RECRUITINGPHASE1, PHASE2
60 participants
INTERVENTIONAL
Birmingham, United States +58 more
Started: Jul 6, 2020
Condition Vasoregulation Function Endothelium in Patients With CML Getting TKI II Generation Bosutinib
NCT05682924RECRUITING
105 participants
OBSERVATIONAL
Moscow, Russia +1 more
Started: Oct 1, 2022
Completed Clinical Trials
13 completed trials for Bosutinib in Chronic Myeloid Leukemia
A Study To Describe The Real World Use Of Bosutinib In The UK And Netherlands
NCT02546375COMPLETED
87 participants
OBSERVATIONAL
Liverpool, United Kingdom +2 more
Started: Jul 15, 2015
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
NCT03128411COMPLETEDPHASE2
64 participants
INTERVENTIONAL
Toyoake, Japan +20 more
Started: May 15, 2017
Safety And Efficacy Of Bosutinib
NCT02501330COMPLETED
702 participants
OBSERVATIONAL
Shibuya-ku, Japan
Started: Jul 1, 2015
Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias
NCT00811070COMPLETEDPHASE2
63 participants
INTERVENTIONAL
Kumamoto, Japan +22 more
Started: Dec 1, 2007
Bosutinib in Elderly Chronic Myeloid Leukemia
NCT02810990COMPLETEDPHASE2
65 participants
INTERVENTIONAL
Alessandria, Italy +44 more
Started: Nov 17, 2016
Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
NCT03106779COMPLETEDPHASE3
233 participants
INTERVENTIONAL
Chicago, United States +87 more
Started: Oct 26, 2017
Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias
NCT00261846COMPLETEDPHASE2
571 participants
INTERVENTIONAL
Duarte, United States +110 more
Started: Jan 18, 2006
Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008
NCT01903733COMPLETEDNA
281 participants
INTERVENTIONAL
Orlando, United States +90 more
Started: Aug 28, 2013
Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database
NCT05286528COMPLETED
1.48K participants
OBSERVATIONAL
Budapest, Hungary
Started: Nov 18, 2020
Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML
NCT00574873COMPLETEDPHASE3
502 participants
INTERVENTIONAL
Anaheim, United States +164 more
Started: Feb 5, 2008
Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis
NCT03831776COMPLETEDPHASE2
212 participants
INTERVENTIONAL
Aalborg, Denmark +17 more
Started: Mar 25, 2019
Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects
NCT01374139COMPLETEDPHASE1
88 participants
INTERVENTIONAL
Singapore, Singapore
Started: Aug 1, 2011
Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects
NCT00759837COMPLETEDPHASE1
27 participants
INTERVENTIONAL
Warsaw, Poland
Started: Oct 1, 2008
Showing 20 of 43 total trials